©2022 Stanford Medicine
OPsumit USers Registry
Recruiting
I'm InterestedTrial ID: NCT02126943
Purpose
Prospective observational drug registry developed to characterize the safety profile
(including primarily potential serious hepatic risks) and to describe clinical
characteristics and outcomes of patients newly treated with Opsumit in the post-marketing
setting.
Official Title
US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice
Stanford Investigator(s)
Roham Zamanian
Professor of Medicine (Pulmonary and Critical Care Medicine)
Eligibility
Inclusion Criteria:
Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days
prior to enrollment visit.
Signed ICF
Exclusion Criteria:
Previous user of Opsumit defined as patient who initiated therapy >30 days prior to
enrollment.
Patients enrolled in any ongoing clinical trials
Intervention(s):
drug: Opsumit (macitentan)
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305